Two mutations of dihydropteridine reductase deficiency.
Two patients with dihydropteridine reductase (DHPR) deficiency, in one case due to the absence of any enzyme protein (DHPR- cross reactive material (CRM)-) and in the other case due to the production of a mutant type devoid of catalytic activity (DHPR- CRM+) were examined. This latter form of malignant phenylketonuria, whose relative frequency seems to be higher in the Italian population, possibly has a worse prognosis. The earlier onset and the greater severity of clinical symptoms are associated with a more pronounced hydroxylation defect, as shown by higher degree of neonatal hyperphenylalaninaemia, unresponsiveness to an oral tetrahydrobiopterin load, lower concentrations of neurotransmitter metabolites, and reduced tyrosine production after an oral phenylalanine load.
D004093:Dihydropteridine Reductase / Q000235:genetics / Q000378:metabolism; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D009154:Mutation; D009247:NADH, NADPH Oxidoreductases / Q000172:deficiency*; D018377:Neurotransmitter Agents / Q000378:metabolism; D010649:Phenylalanine / Q000097:blood; D010661:Phenylketonurias / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D011622:Pterins / Q000378:metabolism; D014443:Tyrosine / Q000097:blood
D018377:Neurotransmitter Agents; D011622:Pterins; D014443:Tyrosine; D010649:Phenylalanine; D005492:Folic Acid; D004093:Dihydropteridine Reductase; D009247:NADH, NADPH Oxidoreductases